AR025308A1 - COMPOSITIONS AND METHODS TO TREAT ALLERGIC AND INFLAMMATORY CONDITIONS WITH YOU. - Google Patents

COMPOSITIONS AND METHODS TO TREAT ALLERGIC AND INFLAMMATORY CONDITIONS WITH YOU.

Info

Publication number
AR025308A1
AR025308A1 ARP000104255A ARP000104255A AR025308A1 AR 025308 A1 AR025308 A1 AR 025308A1 AR P000104255 A ARP000104255 A AR P000104255A AR P000104255 A ARP000104255 A AR P000104255A AR 025308 A1 AR025308 A1 AR 025308A1
Authority
AR
Argentina
Prior art keywords
inflammatory conditions
methods
expectorant
compositions
sedating antihistamine
Prior art date
Application number
ARP000104255A
Other languages
Spanish (es)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR025308A1 publication Critical patent/AR025308A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Abstract

Se describen métodos para tratar y/o prevenir condiciones alérgicas e inflamatorias con tos en humanos que requieran dicho tratamiento y/o prevencion, loscuales comprenden administrar una cantidad efectiva de una antihistamina no sedante encombinaci on con un expectorante; las modalidades que se prefierenincluyen aquellas en las que la antihistamina no sedante es loratadina y el expectorante es ambroxol; se proveen también composiciones farmacéuticas novedosaspara tratar y/o prevenircondiciones alérgicas e inflamatorias con tos en humanos, las cuales comprenden una cantidad efectiva de una antihistamina no sedanteen combinacion con un expectorante y un vehículo farmacéuticamente aceptable.Methods for treating and / or preventing allergic and inflammatory conditions with cough in humans that require such treatment and / or prevention are described, which include administering an effective amount of a non-sedating antihistamine encased with an expectorant; preferred modalities include those in which the non-sedating antihistamine is loratadine and the expectorant is ambroxol; Novel pharmaceutical compositions are also provided to treat and / or prevent allergic and inflammatory conditions with coughs in humans, which comprise an effective amount of a non-sedating antihistamine in combination with an expectorant and a pharmaceutically acceptable carrier.

ARP000104255A 2000-03-30 2000-08-17 COMPOSITIONS AND METHODS TO TREAT ALLERGIC AND INFLAMMATORY CONDITIONS WITH YOU. AR025308A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19331000P 2000-03-30 2000-03-30

Publications (1)

Publication Number Publication Date
AR025308A1 true AR025308A1 (en) 2002-11-20

Family

ID=22713096

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104255A AR025308A1 (en) 2000-03-30 2000-08-17 COMPOSITIONS AND METHODS TO TREAT ALLERGIC AND INFLAMMATORY CONDITIONS WITH YOU.

Country Status (13)

Country Link
CN (1) CN1422162A (en)
AR (1) AR025308A1 (en)
AU (2) AU4786701A (en)
BR (1) BR0003648A (en)
CO (1) CO5200779A1 (en)
CR (1) CR6232A (en)
NZ (1) NZ520826A (en)
PA (1) PA8500101A1 (en)
PE (1) PE20010576A1 (en)
SG (1) SG96611A1 (en)
TW (1) TWI243671B (en)
WO (1) WO2001074341A2 (en)
ZA (1) ZA200102605B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1323662C (en) * 2004-06-18 2007-07-04 江苏恒瑞医药股份有限公司 Pharmaceutical composition containing ambroxol and erdosteine or acetylcysteine and application thereof
WO2005123052A1 (en) * 2004-06-18 2005-12-29 Jiangsu Hengrui Medicine Co., Ltd. Drug composition containing ambroxol and erdosteine or acetylcysteine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4783465A (en) * 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4829064A (en) * 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
EP0719156A1 (en) * 1993-09-07 1996-07-03 The Procter & Gamble Company Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive
US6160020A (en) * 1996-12-20 2000-12-12 Mcneill-Ppc, Inc. Alkali metal and alkaline-earth metal salts of acetaminophen

Also Published As

Publication number Publication date
PE20010576A1 (en) 2001-05-08
TWI243671B (en) 2005-11-21
ZA200102605B (en) 2001-10-03
AU2001247867B2 (en) 2005-09-01
SG96611A1 (en) 2003-06-16
CO5200779A1 (en) 2002-09-27
WO2001074341A2 (en) 2001-10-11
CN1422162A (en) 2003-06-04
PA8500101A1 (en) 2002-09-17
NZ520826A (en) 2004-07-30
CR6232A (en) 2008-12-01
AU4786701A (en) 2001-10-15
WO2001074341A3 (en) 2002-05-16
BR0003648A (en) 2002-01-02

Similar Documents

Publication Publication Date Title
AR028296A1 (en) SYNERGISTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
UY28041A1 (en) LOW DOSE METHODS FOR THE TREATMENT OF DISORDERS IN WHICH TNFA'S ACTIVITY IS HARMFUL.
NO20050807L (en) Pharmaceutical compositions including dextromethorphan and quinidine for the treatment of neurological disorders
CY1114133T1 (en) Substituted c-phenyl-D-lactams and their related uses
NO993847D0 (en) Methods and Compositions for the Treatment of Allergic Asthma and Other Diseases Using Descarboethoxyloratadine
BR0207961A (en) Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases.
NO20034094L (en) Compositions comprising an anti-diarrheal agent and an epothilone or epothilone derivative
ATE472325T1 (en) INTRACORPORAL MEDICATIONS FOR THE PHOTODYNAMIC TREATMENT OF DISEASES
AR026610A1 (en) A PIRROLIDINACETAMIDE DERIVATIVE ONLY OR IN COMBINATION FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
AR012671A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PROPHYLAXIS OF THE CONSTIPATION, THE USES OF SUCH COMPOSITIONS AND THE PROCESSES TO PREPARE THEM
GEP20053657B (en) Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds, Pharmaceutical Compositions Thereof
ECSP045153A (en) METHOD AND COMPOSITION TO INCREASE THE POWER OF A NARCOTIC ANALGEST.
AR008799A1 (en) VACCINE COMPOSITION TO PREVENT OR TREAT MALARIA; USE OF SUCH COMPOSITION TO PREPARE DRUGS AND METHOD FOR SUCH PROPHYLAXIS AND SUCH TREATMENT
NO20054216L (en) Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention
BR0313611A (en) Use of the ciclesonide and antihistamine combination for the treatment of allergic rhinitis
AR028502A1 (en) TREATMENT OF ALLERGIC INFLAMMATORY CONDITIONS
AR025308A1 (en) COMPOSITIONS AND METHODS TO TREAT ALLERGIC AND INFLAMMATORY CONDITIONS WITH YOU.
CO5580773A2 (en) ROSUVASTATINA IN PRE DEMENT STATES
RS50681B (en) A combination of a taxane and cyclin-dependent kinase inhibitor
MX9302985A (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PROPHYLAXIS OF ANXIETY.
AR030660A1 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AN ILLNESS ASSOCIATED WITH AN EXCESS OF IL-12 PRODUCTION
EA200300430A1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING EPINASTINES AND PSEVDOEDFEDRIN
AR027677A1 (en) A THERAPEUTIC PHARMACEUTICAL COMPOSITION THAT INCLUDES CAMPTOTECHINE AND CYCLOFOSPHAMIDE FOR THE TREATMENT OF CANCER
CL2006002620A1 (en) Composition for the prevention and treatment of infections caused by coccidia in animals consisting of yolk with anti-eimeria immunoglobulas, water and a preservative; and method for the prevention of infections caused by coccidia parasites comprising oral administration of one or more anti eimeria immunoglobulins.
DE60304678D1 (en) IDRAPARINUX (SANORG 34006) FOR THE TREATMENT AND SECONDARY PROPHYLAXIS OF THROMBOEMBOLIENTS IN PATIENTS WITH DEEP VENENTROMBOSIS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal